NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund research that will use a range of 'omics technologies to develop and validate biomarkers for malignancies of the blood under two new grant programs.

NCI will use five-year R01 and two-year R21 grant mechanisms to support scientists developing genomic, proteomic, epigenomic, and transcriptomic delivery and development methods, as well as the use of standardized biospecimens for validation studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.